NICE recommends aflibercept for AMD

New guidance from NICE approves the use of aflibercept (Eylea) in patients with wet age-related macular degeneration (AMD).

In two double-blind, phase III studies, the safety profile of aflibercept was comparable to that of ranibizumab, with similar rates of both ocular and non-ocular adverse events.
In two double-blind, phase III studies, the safety profile of aflibercept was comparable to that of ranibizumab, with similar rates of both ocular and non-ocular adverse events.

The use of aflibercept (Eylea) has the same restrictions as ranibizumab when used for the treatment of wet AMD, specifically the following criteria must apply in the eye to be treated:

  • the best-corrected visual acuity is between 6/12 and 6/96
  • there is no permanent structural damage to the fovea
  • the lesion size is no larger than 12 disc areas in greatest linear dimension
  • there is evidence of recent presumed disease progression (blood vessel growth, as indicated by fluorescein angiography, or recent visual acuity changes)

The drug must be provided by the manufacturer with the discount as agreed in the patient access scheme.

View Eylea drug record

NICE guidance on aflibercept solution for injection for treating wet age-related macular degeneration

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more